Phase I study of 4-demethoxydaunorubicin by oral route in patients with advanced cancer.
In a phase I trial 4-demethoxydaunorubicin (4-dm DNR) was administered as oral capsules once a week to 51 adults with advanced mainly gastrointestinal solid tumors. No fatal toxicity was observed at doses up to 25.0 mg/m2. Dose-limiting granulocytopenia and non-hematologic toxicity developed at dosages greater than or equal to 22.5 mg/m2. No response to the therapy was observed. The plasma concentrations of 4-dm DNR were measured in 4 of the patients.
Krarup-Hansen
A
A
Department of Oncology Ona, Finsen Institute, Copenhagen, Denmark.
Andersen
E
E
Elbaek
K
K
Rasmussen
S N
SN
Dalmark
M
M
D000284:Administration, Oral; D000328:Adult; D000368:Aged; D004341:Drug Evaluation; D005260:Female; D006801:Humans; D015255:Idarubicin / Q000008:administration & dosage / Q000009:adverse effects* / Q000493:pharmacokinetics; D008297:Male; D008875:Middle Aged; D009369:Neoplasms / Q000188:drug therapy*
D015255:Idarubicin